Scrip | Pharmaceutical Market & Competitor Insights :: Scrip
Scrip is operated by Pharma Intelligence UK Limited, a company registered in England and Wales. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
The company recently reported a late-stage success with its COVID-19 and flu combo vaccine, with plans to bring it to market next year. Additionally, Arexvy was approved by the US FDA for adults aged 50-59 with specific medical conditions putting them at higher risk of severe RSV. Moreover, there have been recent developments in the pharmaceutical industry, such as the end of a cancer deal between the company and SpringWorks.
Future of Pharmaceutical Innovations
While injectables have been receiving significant attention, analysts foresee a promising future for Sagimet’s oral denifanstat, potentially as a foundational therapy in combination with other treatments for MASH. Experts in the biopharma field, including Nobel Laureate Professor Jack Szostak, share insights on emerging innovation ecosystems and the potential growth of the industry, particularly in India.
Furthermore, discussions on VC investments, regulatory frameworks ensuring safety, and the role of AI platforms have been prominent topics within the sector.
For more coverage from Scrip's team in Asia, you can visit here.
Commercial and R&D Developments
Insights and perspectives on commercial, R&D, deal-making, and business strategy developments have been highlighted. Clinical trial results that excite stock market investors undergo rigorous analysis by big pharma deal-makers, emphasizing the importance of pipeline renewal.
Several deals involving major pharmaceutical companies like GSK, Eli Lilly, and Gilead have shaped the industry landscape. Pipeline Watch provides a weekly overview of late-stage clinical trial events and approvals within the pharmaceutical and biotech sectors.
Moreover, the podcast series commemorating 20 years of the Scrip Awards sheds light on the innovative aspects of the biopharma sector.
Industry Trends and Analysis
An analysis of top-selling drugs and their revenue milestones, along with the impact of indication expansion on revenue growth, showcases the dynamics of the pharmaceutical market. Discussions on regulatory strategies and drug development best practices are crucial in navigating the evolving industry landscape.
Companies are exploring innovative mechanisms to develop new drugs, with a focus on addressing unmet medical needs. As the industry progresses, collaboration and strategic partnerships play a pivotal role in driving innovation and growth.
Stay informed about the latest advancements in the pharmaceutical industry and the transformative technologies revolutionizing drug development, delivery, and manufacturing.
